Your session is about to expire
← Back to Search
Taletrectinib for Non-Small Cell Lung Cancer (TRUST-II Trial)
TRUST-II Trial Summary
This trial is studying taletrectinib to see how well it works in treating patients with non-small cell lung cancer.
TRUST-II Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTRUST-II Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TRUST-II Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Taletrectinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Are there any openings for new participants in this trial?
"Absolutely. Evidence from clinicaltrials.gov confirms that this research, which was first published on September 1st 2021, is still recruiting subjects. A total of 119 participants are needed across 25 distinct medical sites."
What is the scope of enrolment for this research project?
"AnHeart Therapeutics Inc. need to enlist 119 participants that meet their study's criteria, and are running the trial from multiple sites such as Keck Medicine of University of Southern California in LA and Moores Cancer Center at UC San Diego in La Jolla, Minnesota."
What deleterious effects have been observed when taking Taletrectinib?
"We at Power assign a safety rating of 2 to taletrectinib, as there is some evidence backing its safe use but none that speaks to efficacy."
How many healthcare settings are participating in this trial?
"This trial has 25 active clinical sites including Keck Medicine of University of Southern California in Los Angeles, Moores Cancer Center at UC San Diego in La Jolla and Mayo Clinic in Rochester. Additionally, there are 22 other operating centres."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger